On May 20, BeiGene rose 3.15% in regular trading, trading at HK$180.2 per share, with trading volume of approximately HK$607 million. The rebound follows consecutive sessions of sector-wide selling pressure and is driven by strong Q1 financial results and bullish analyst coverage.

BeiGene reported Q1 global revenue of US$1.513 billion, up 35.5% year-over-year, exceeding the market consensus estimate of US$1.44 billion. GAAP net profit reached US$227 million, representing a US$226 million improvement year-over-year, with the beat primarily attributed to better-than-expected expense control. Free cash flow came in at US$161 million. Management raised full-year revenue guidance by US$1 billion to a range of US$6.3–6.5 billion.

Multiple investment banks issued bullish ratings. CICC maintained an Outperform rating with an H-share target price of HK$250. Citi maintained a Buy rating and raised its U.S.-listed target price from US$430 to US$453. The market appears to be repricing BeiGene as it transitions from a high-investment-stage biotech into a profitable global commercial-stage pharmaceutical company backed by sustainable cash flow generation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)